Identity of those reporting medical device adverse events not to be revealed

  • India’s apex drug regulator is collating information on adverse events due to medical devices to take timely action against manufacturers and ensure appropriate measures to mitigate risks to public health as the number of such incidents rise.

Priyanka Sharma
Published14 Oct 2024, 07:56 PM IST
The regulatory action is aimed at stricter surveillance of side effects from medical devices. (Bloomberg)
The regulatory action is aimed at stricter surveillance of side effects from medical devices. (Bloomberg)

New Delhi: India’s apex drug regulator is collating information on adverse events due to medical devices to take timely action against manufacturers and ensure appropriate measures to mitigate risks to public health as the number of such incidents rise.

The Drugs Controller of General of India has issued a prescribed format to collect information on undesired effects from medical devices and in-vitro-medical devices (IVDs), ensuring that the identity of the ‘patient’ or the ‘complainant’ will not be made public. The proforma has to be filled with details such as description of the medical device with details including the brand name, manufacturer, importer or distributor. 

The DCGI has urged people to send the duly filled form to the Indian Pharmacopoeia Commission, a body under the health ministry, which runs the government’s Materiovigilance Programme of India (MvPI) platform to monitor adverse events associated with medical devices in India.

Also read: Has your medical device been tested by a qualified officer or a pharmacist? The regulator wants to act

The regulatory action is aimed at stricter surveillance of side effects from medical devices, a market that is estimated to expand from $11 billion to $50 billion by 2030. Mint earlier reported about DCGI directing all medical device licence holders and manufacturers to report any adverse events related to life-saving medical equipment on the MvPI platform.

Safety concerns

Unlike drugs, absolute safety in medical devices—which are engineering, not chemical, products — may not be possible, according to said Rajiv Nath , forum coordinator, AiMeD, an umbrella body of medical device manufacturers in India.

There needs to be post marketing surveillance of serious adverse events that lead to death or injuries requiring surgical intervention, he said. What’s important that such events have to be reported to manufacturers to enable faster and direct redressal or the Indian Pharmacopoeia Commission or the regulator, using the feedback for systemic reviews, he said.

Medical devices are therapeutic, diagnostic, therapeutic & diagnostic, implantable, non-implantable, invasive & non-invasive, single-use device, reusable, sterile & non-sterile, and for personal use and homecare.

Also read: Budget may unveil scheme to incentivize medical gear makers

Nath said the reports on adverse events from such devices should not result in witch-hunting and a trust factor needs to be created to persecute the one reporting—whether it’s a health care provider or patient or the manufacturer itself.

Lack of clarity

DCGI, in its public notice, said the submission of a Medical Devices Adverse Event (MDAE) does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the adverse event and also “does not have any legal implication on the reporter”.

 “The patient/reporter’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the patient/reporter’s identity in response to a request from the public,” it said.

Citing regulations in the US and the European Union, Nath also stressed on clarity for “what’s reportable and what’s not—what’s a serious adverse event and what’s a non-serious adverse event”.

Also read: India’s top drug regulator cracks the whip on similar sounding brand names

“Currently there’s a lot of confusion and lack of clarity at various levels, so either there’s under-reporting or an extreme of over reporting at some organizations or not reporting to manufacturer but reporting to regulators,” he said. "Webinars and public education will help to bring clarity and build a trust factor.”

Catch all the Business News, Politics news,Breaking NewsEvents andLatest News Updates on Live Mint. Download TheMint News App to get Daily Market Updates.

MoreLess
First Published:14 Oct 2024, 07:56 PM IST
Business NewsPoliticsPolicyIdentity of those reporting medical device adverse events not to be revealed

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel share price

    149.70
    07:18 PM | 1 NOV 2024
    1.05 (0.71%)

    Indian Oil Corporation share price

    145.00
    07:19 PM | 1 NOV 2024
    2.3 (1.61%)

    Tata Power share price

    445.20
    07:19 PM | 1 NOV 2024
    5.15 (1.17%)

    Bandhan Bank share price

    183.65
    07:10 PM | 1 NOV 2024
    1.4 (0.77%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Rainbow Childrens Medicare share price

    1,545.00
    06:59 PM | 1 NOV 2024
    -67.25 (-4.17%)

    ICICI Securities share price

    833.45
    06:59 PM | 1 NOV 2024
    -32.85 (-3.79%)

    Vijaya Diagnostic Centre share price

    966.70
    06:59 PM | 1 NOV 2024
    -30.35 (-3.04%)

    Narayana Hrudayalaya share price

    1,235.60
    06:59 PM | 1 NOV 2024
    -36.75 (-2.89%)
    More from Top Losers

    Brigade Enterprises share price

    1,244.80
    07:19 PM | 1 NOV 2024
    71.75 (6.12%)

    PCBL share price

    432.15
    07:17 PM | 1 NOV 2024
    21.35 (5.2%)

    Piramal Pharma share price

    281.85
    07:17 PM | 1 NOV 2024
    13.45 (5.01%)

    Jubilant Pharmova share price

    1,273.00
    06:59 PM | 1 NOV 2024
    60.65 (5%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      80,565.00-790.00
      Chennai
      80,571.00-790.00
      Delhi
      80,723.00-790.00
      Kolkata
      80,575.00-790.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L-0.06
      Chennai
      101.23/L0.43
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in Politics

        HomeMarketsPremiumInstant LoanMint Shorts